Residency · Residency · Critical Care

Cardiac Arrest and Post-Resuscitation Care

In-Hospital Cardiac Arrest (IHCA)

Epidemiology

In-hospital cardiac arrest occurs at a rate of approximately 9 to 10 per 1,000 hospital admissions in the United States, corresponding to roughly 290,000 events annually. The distribution of initial cardiac rhythms differs substantially from out-of-hospital cardiac arrest, with pulseless electrical activity comprising 40 to 50 percent, asystole 25 to 30 percent, and ventricular fibrillation or pulseless ventricular tachycardia accounting for only 20 to 25 percent of cases. Overall survival to hospital discharge is approximately 25 percent, with significantly better outcomes for shockable rhythms at approximately 40 percent compared to pulseless electrical activity at approximately 12 percent and asystole at approximately 10 percent. Witnessed and monitored arrests carry meaningfully better outcomes than unwitnessed events, underscoring the value of continuous telemetry monitoring in at-risk patients.

Recognition and Activation

Rapid recognition is the first and most critical step in cardiac arrest management. The pulse check should take no more than 10 seconds, and if a pulse is absent or uncertain, chest compressions should be initiated immediately without further delay. The code team should be activated and a defibrillator obtained simultaneously. Time to first chest compression and time to first defibrillation for shockable rhythms remain the most modifiable predictors of survival, with each minute of delay in defibrillation reducing survival by approximately 7 to 10 percent.

Advanced Cardiac Life Support (ACLS)

High-Quality CPR

The foundation of successful resuscitation is the delivery of high-quality chest compressions. Compressions should be delivered at a rate of 100 to 120 per minute with a depth of 5 to 6 cm in adults, allowing complete chest recoil between compressions to permit venous refilling of the heart. Interruptions in compressions must be minimized, with a target CPR fraction exceeding 80 percent, representing the proportion of total arrest time during which compressions are actively being delivered. Once an advanced airway is in place, ventilation should be delivered at 10 breaths per minute without synchronization with compressions, allowing continuous chest compressions. Compressors should be rotated every 2 minutes to prevent fatigue-induced deterioration in compression quality. End-tidal CO2 monitoring during CPR provides invaluable real-time information: an ETCO2 below 10 mmHg after 20 minutes of resuscitation is associated with futility, while an ETCO2 above 20 mmHg suggests either adequate CPR quality or the return of spontaneous circulation.

Shockable Rhythms (VF/Pulseless VT)

The management of ventricular fibrillation and pulseless ventricular tachycardia centers on early defibrillation combined with high-quality CPR. Biphasic defibrillation at 120 to 200 joules, per manufacturer specifications, should be delivered as soon as the rhythm is identified, with energy escalation if the first shock is unsuccessful. The resuscitation cycle follows a structured sequence: 2 minutes of CPR followed by a rhythm check, defibrillation if VF or pVT persists, then another 2 minutes of CPR. Epinephrine at 1 mg intravenously every 3 to 5 minutes is initiated after the second failed defibrillation attempt. Amiodarone at 300 mg intravenously for the first dose and 150 mg for a subsequent dose is administered after the third failed defibrillation, with lidocaine at 1 to 1.5 mg/kg as an alternative. For refractory ventricular fibrillation, advanced strategies including double sequential defibrillation using two defibrillators simultaneously, esmolol at 500 mcg/kg bolus, and stellate ganglion block may be considered, though the evidence supporting these approaches remains limited.

Non-Shockable Rhythms (PEA/Asystole)

The management of pulseless electrical activity and asystole focuses on CPR and the identification of reversible causes. Epinephrine at 1 mg intravenously every 3 to 5 minutes is initiated immediately, as there is no shockable rhythm warranting defibrillation. Defibrillation in asystole is not only unhelpful but harmful. The clinical challenge with PEA lies in the rapid identification and treatment of reversible causes, guided by the H's and T's mnemonic. A narrow QRS complex during PEA should prompt consideration of mechanical causes including pulmonary embolism, cardiac tamponade, and tension pneumothorax. A wide QRS complex during PEA raises suspicion for hyperkalemia and sodium channel blocker toxicity.

Reversible Causes (H's and T's)

A systematic evaluation for reversible causes must proceed in parallel with standard ACLS interventions. Hypovolemia is treated with fluid boluses and blood products. Hypoxia requires confirmation of adequate ventilation and verification of endotracheal tube position. Hydrogen ion excess from severe acidosis may warrant sodium bicarbonate administration, though this is reserved for known severe acidosis or hyperkalemia. Hyperkalemia and hypokalemia are treated with calcium gluconate at 3 grams intravenously, insulin with dextrose, and nebulized albuterol. Hypothermia requires active rewarming. Tension pneumothorax demands immediate needle decompression followed by chest tube placement. Cardiac tamponade requires echo-guided pericardiocentesis. Toxin ingestions may require specific antidotes including naloxone, lipid emulsion, and digoxin-specific Fab fragments. Pulmonary thrombosis warrants systemic thrombolysis with tPA at 50 mg bolus, with CPR continued for 60 to 90 minutes after thrombolytic administration to allow sufficient time for drug effect. Coronary thrombosis should prompt consideration of transfer to a PCI-capable facility.

<image>ACLS algorithm flowchart showing the two pathways for cardiac arrest management. Left pathway (shockable - VF/pVT): CPR → rhythm check → shock → CPR 2 min → epinephrine after 2nd shock → amiodarone after 3rd shock → repeat cycle. Right pathway (non-shockable - PEA/asystole): CPR → rhythm check → epinephrine immediately → CPR 2 min → assess for reversible causes → repeat. Central connecting arrows showing rhythm can convert between pathways. Include H's and T's mnemonic in a reference box. Show ETCO2 waveform with annotation: >20 mmHg = adequate CPR, sharp rise = ROSC, <10 mmHg after 20 min = poor prognosis. Drug doses and timing clearly labeled at each intervention point.</image>

Special Cardiac Arrest Scenarios

Cardiac Arrest in PE

When massive pulmonary embolism is suspected as the cause of cardiac arrest, systemic thrombolysis should be administered during ongoing CPR. Alteplase at 50 mg as an intravenous bolus is the standard approach, with CPR continued for at least 60 to 90 minutes after administration to allow time for clot dissolution. CPR itself generates some pulmonary blood flow that may help redistribute the thrombolytic agent to the clot. If ROSC is not achieved and pulmonary embolism is confirmed, consideration should be given to surgical embolectomy or catheter-directed therapy, potentially with extracorporeal CPR support.

Cardiac Arrest in Hyperkalemia

Hyperkalemia-induced cardiac arrest requires a specific and aggressive pharmacological approach. Calcium gluconate at 30 mL of 10 percent solution, providing 3 grams, should be administered intravenously as a membrane stabilizer with an onset of 1 to 3 minutes. Sodium bicarbonate at 50 to 100 mEq intravenously shifts potassium intracellularly. Regular insulin at 10 units intravenously with 50 mL of D50W provides an additional intracellular shift. Nebulized albuterol at 10 to 20 mg further reduces serum potassium. If ROSC is achieved, hemodialysis provides definitive potassium removal.

ECPR (Extracorporeal CPR)

Extracorporeal CPR involves the initiation of venoarterial ECMO during ongoing cardiopulmonary resuscitation in patients with refractory cardiac arrest. The ARREST trial of 2020 compared ECPR against standard ACLS for refractory out-of-hospital cardiac arrest with ventricular fibrillation and demonstrated a striking survival difference of 43 percent versus 7 percent, though the trial was small with only 30 patients. The Prague OHCA study of 2022 examined an invasive approach including ECPR and found no overall survival benefit compared to standard care, but did demonstrate improved neurological outcomes among survivors. Patient selection is critical: ideal candidates have a witnessed arrest, a shockable initial rhythm, less than 60 minutes of low-flow CPR, no terminal illness, and age below 70. ECPR requires pre-established institutional protocols, a trained cannulation team, and catheterization laboratory availability, with the goal of initiating support before 60 minutes of low-flow time and ideally before 45 minutes.

Post-Resuscitation Care (Post-Cardiac Arrest Syndrome)

Pathophysiology

The post-cardiac arrest syndrome represents a whole-body ischemia-reperfusion injury affecting all organ systems. It comprises four interrelated components: post-cardiac arrest brain injury from excitotoxicity, oxidative stress, and apoptosis, which is the primary determinant of long-term neurological outcome; post-cardiac arrest myocardial dysfunction, manifesting as global hypokinesis or stunning that typically appears within hours of ROSC and recovers over 24 to 72 hours; the systemic ischemia-reperfusion response, which produces a sepsis-like inflammatory state with vasodilation and capillary leak; and the persistent precipitating pathology, such as an occluded coronary artery or massive pulmonary embolism, that caused the arrest and may require specific intervention.

Targeted Temperature Management (TTM)

Evolution of Evidence

The evidence for targeted temperature management has evolved substantially over two decades. The HACA trial of 2002 and the study by Bernard and colleagues in 2002 established that cooling to 32 to 34 degrees Celsius improved neurological outcomes after out-of-hospital cardiac arrest with ventricular fibrillation. The TTM trial of 2013 compared 33 degrees against 36 degrees Celsius and found no difference in mortality or neurological outcome, calling into question whether active cooling below normothermia was necessary. The TTM2 trial of 2021 provided the most definitive evidence, comparing hypothermia at 33 degrees Celsius against normothermia at 37.5 degrees Celsius with active fever prevention, and finding no difference in 6-month mortality at 50 percent versus 48 percent or in neurological outcome. The HYPERION trial of 2019 examined non-shockable rhythms specifically and found that hypothermia to 33 degrees Celsius improved favorable neurological outcome compared to normothermia at 10.2 percent versus 5.7 percent, though overall survival rates remained poor.

Current Recommendations (AHA 2023)

Current American Heart Association guidelines recommend targeted normothermia with active prevention of fever above 37.5 degrees Celsius for at least 72 hours after ROSC in all comatose cardiac arrest survivors. Targeted temperature management at 32 to 36 degrees Celsius remains a reasonable option for patients who remain comatose after ROSC, though this carries a weaker recommendation than in previous guidelines. When active cooling is employed, the target temperature should be maintained for at least 24 hours. Patients who are spontaneously hypothermic after arrest should not be actively rewarmed unless their temperature falls below 32 degrees Celsius. Rewarming, when required, should proceed slowly at 0.25 to 0.5 degrees Celsius per hour.

Practical TTM Implementation

Surface cooling systems such as the Arctic Sun and cooling blankets achieve target temperature more slowly, while intravascular cooling devices such as the Thermogard provide more precise temperature control. The target temperature should ideally be reached within 4 to 6 hours of ROSC. Shivering management is essential and employs a stepwise approach including acetaminophen, buspirone, meperidine, and dexmedetomidine, escalating to neuromuscular blockade if refractory. Complications of temperature management include bradycardia, hypokalemia from intracellular potassium shift during cooling, hyperkalemia during rewarming, coagulopathy, and increased infection risk.

Hemodynamic Management

Hemodynamic support targets a mean arterial pressure of at least 65 to 70 mmHg, with some guidelines suggesting a target of 80 mmHg or greater for optimizing cerebral perfusion, though evidence for higher targets remains limited. Post-arrest myocardial dysfunction typically requires a combination of inotropes such as dobutamine and vasopressors such as norepinephrine. Even brief episodes of hypotension worsen neurological outcomes and must be aggressively prevented and treated. Regarding coronary angiography, immediate catheterization is indicated for patients with ST-segment elevation myocardial infarction. For patients without ST-segment elevation, the timing of angiography has been clarified by the COACT trial of 2019 and the TOMAHAWK trial of 2021, both of which demonstrated no benefit from immediate angiography compared to a delayed approach, with the TOMAHAWK trial suggesting possible harm from the immediate strategy.

Ventilatory Management

Post-cardiac arrest ventilatory management targets normocapnia with a PaCO2 of 35 to 45 mmHg, as hypocapnia reduces cerebral blood flow and hypercapnia increases intracranial pressure. Normoxia should be targeted with a PaO2 of 75 to 100 mmHg, as hyperoxia with a PaO2 exceeding 300 mmHg has been associated with worse neurological outcomes. Lung-protective ventilation with tidal volumes of 6 to 8 mL/kg ideal body weight should be employed.

<image>Post-cardiac arrest care bundle timeline showing interventions from ROSC through 72+ hours. Horizontal timeline with vertical intervention tracks: (1) Airway/breathing: waveform capnography, ventilator settings, PaCO2 35-45 target, SpO2 94-98%; (2) Circulation: MAP target, vasopressors/inotropes, coronary angiography decision tree (STEMI → immediate cath, no STEMI → delayed/selective), echocardiogram; (3) Temperature: TTM initiation within 4-6 hours, maintenance at target for 24 hours, slow rewarming 0.25 degrees/hr, active fever prevention for 72 hours; (4) Neurology: continuous EEG monitoring, avoid sedation interruption in first 72 hours, neuroprognostication timeline at >=72 hours; (5) Metabolic: glucose management, electrolyte correction, seizure treatment. Include specific drug doses and target values at each time point.</image>

Neuroprognostication

Timing

Neuroprognostication must not be performed before at least 72 hours after the achievement of normothermia, or at least 72 hours after rewarming if targeted temperature management was employed. Sedation and neuromuscular blockade confound all clinical predictors, and adequate washout of these agents must be ensured before any prognostic assessment is considered reliable. A multimodal approach incorporating multiple independent assessment modalities is required, as no single test is sufficient to predict neurological outcome with adequate certainty.

Clinical Examination (>= 72 hours)

Bilateral absence of the pupillary light reflex carries a false positive rate of 0 percent, representing the highest specificity for poor outcome among clinical examination findings. Bilateral absence of the corneal reflex carries a false positive rate of approximately 2 percent. Absent or extensor motor response, classified as M1 or M2 on the Glasgow Coma Scale, has a false positive rate of 10 to 20 percent when used in isolation and is therefore insufficient as a sole prognostic indicator. Myoclonus status epilepticus occurring within 72 hours was previously considered uniformly fatal, but the recognition of Lance-Adams syndrome, a form of post-hypoxic myoclonus with good neurological outcome, means that myoclonus alone should not be used as the sole basis for prognostication.

Electrophysiology

Electroencephalographic findings associated with poor prognosis include a suppressed background, burst-suppression pattern, and status epilepticus. Absence of EEG reactivity to external stimulation is associated with poor outcome with a false positive rate of approximately 3 percent. Continuous EEG monitoring for at least 24 hours is recommended to detect non-convulsive seizures, which occur in 12 to 22 percent of post-cardiac arrest patients. Somatosensory evoked potentials are the most reliable single electrophysiological predictor: bilateral absence of the N20 cortical response carries a false positive rate of less than 1 percent, making it the most specific individual test available for predicting poor neurological outcome.

Biomarkers

Neuron-specific enolase at levels above 33 mcg/L measured at 48 to 72 hours is associated with poor neurological outcome. The trend of NSE values is more informative than any single measurement, and caution is required as hemolysis causes false elevation. S100B protein is less extensively validated than NSE but values above 1.0 mcg/L at 24 to 48 hours suggest poor outcome.

Neuroimaging

Brain MRI with diffusion-weighted imaging demonstrating extensive cortical and deep gray matter diffusion restriction is a strong predictor of poor neurological prognosis, with optimal imaging timing at 3 to 7 days post-arrest. CT findings of loss of gray-white matter differentiation and diffuse cerebral edema are associated with poor prognosis. A gray-white matter ratio below 1.1 on CT is an established threshold for predicting poor outcome.

Multimodal Approach

The cornerstone of ethical neuroprognostication is the combination of at least two independent modalities, each with a false positive rate below 5 percent for predicting poor outcome. Potential confounders including sedation, hypothermia, metabolic derangements, and hepatic or renal dysfunction must be systematically considered and excluded. The phenomenon of the self-fulfilling prophecy, in which early withdrawal of life-sustaining treatment prevents the observation of potential recovery, represents a recognized and well-documented problem that mandates patience and adherence to timing guidelines.

Key Clinical Pearls

• High-quality CPR (rate 100-120, depth 5-6 cm, full recoil, minimal interruptions) is the most important determinant of cardiac arrest survival
• ETCO2 during CPR is the best real-time indicator of CPR quality and can signal ROSC (sudden rise from baseline)
• For refractory VF: consider double sequential defibrillation, esmolol, or ECPR in eligible patients
• Post-arrest coronary angiography should be immediate for STEMI but NOT for non-STEMI (COACT, TOMAHAWK trials)
• TTM2 shifted practice toward active fever prevention (normothermia) rather than mandatory hypothermia — either approach is acceptable
• Neuroprognostication requires multimodal assessment at >= 72 hours after normothermia with adequate sedation washout
• Bilateral absent N20 on SSEPs is the most reliable single predictor of poor neurological outcome (FPR <1%)
• Resist pressure for early prognostication — self-fulfilling prophecy from premature WLST is a recognized problem

References

1. Panchal AR, Bartos JA, Cabanas JG, et al. Part 3: adult basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2020;142(16_Suppl_2):S366-S468.
2. Dankiewicz J, Cronberg T, Lilja G, et al. Hypothermia versus normothermia after out-of-hospital cardiac arrest. N Engl J Med. 2021;384(24):2283-2294.
3. Lemkes JJ, Janssens GN, van der Hoeven NW, et al. Coronary angiography after cardiac arrest without ST-segment elevation. N Engl J Med. 2019;380(15):1397-1407.
4. Nolan JP, Sandroni C, Bottiger BW, et al. European Resuscitation Council and European Society of Intensive Care Medicine guidelines 2021: post-resuscitation care. Resuscitation. 2021;161:220-269.
5. Yannopoulos D, Bartos J, Raveendran G, et al. Advanced reperfusion strategies for patients with out-of-hospital cardiac arrest and refractory ventricular fibrillation (ARREST): a phase 2, single centre, open-label, randomised controlled trial. Lancet. 2020;396(10265):1807-1816.

Read this lecture as Markdown